文献速递淋巴瘤

双打击淋巴瘤的治疗策略

How I treat double-hit lymphoma.
PubMed 文献 · Blood · 2017-06-09

世界卫生组织2016年淋巴瘤分类将涉及MYC与BCL-2或BCL-6易位的高级别B细胞淋巴瘤单独列出,此类双打击淋巴瘤占弥漫大B细胞淋巴瘤不足10%,标准化学免疫治疗预后差且中枢神经系统受累及进展风险增加,回顾性研究强烈提示强化诱导方案可能带来更优结局,目前尚无前瞻性试验。

要点

  • 双打击淋巴瘤占弥漫大B细胞淋巴瘤不足10%,需与双表达淋巴瘤区分。
  • 标准化学免疫治疗下双打击淋巴瘤预后差,中枢神经系统受累及进展风险增加。
  • 回顾性研究强烈提示强化诱导方案可能带来更优结局,尚无前瞻性试验。

核心结论

  • 双打击淋巴瘤在标准化学免疫治疗下预后差,回顾性研究强烈提示强化诱导方案可能带来更优结局,目前尚无已发表的前瞻性试验。

研究设计与样本

  • 本文为综述,回顾作者对双打击淋巴瘤评估与治疗的方法,并展望将合理靶向药物纳入治疗武器库的未来临床试验。

主要发现

  • 世界卫生组织2016年淋巴瘤分类修订版将涉及MYC与BCL-2或BCL-6易位的高级别B细胞淋巴瘤单独列出,区别于弥漫大B细胞淋巴瘤。
  • 此类淋巴瘤占弥漫大B细胞淋巴瘤不足10%,称为双打击淋巴瘤,若3种重排均存在则称为三打击淋巴瘤。
  • 双打击淋巴瘤需与双表达淋巴瘤区分,后者通过免疫组织化学显示MYC与BCL-2和/或BCL-6表达增加,采用不同截断百分比定义阳性。
  • 双打击淋巴瘤患者接受标准化学免疫治疗预后差,中枢神经系统受累及进展风险增加。
  • 双打击淋巴瘤可能由 underlying 惰性淋巴瘤转化而来。

临床怎么用

  • 作者在文中回顾其评估与治疗双打击淋巴瘤的方法,并关注将合理靶向药物纳入未来临床试验。

局限性

  • 双打击淋巴瘤尚无已发表的前瞻性试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2016 revision of the World Health Organization (WHO) classification for lymphoma has included a new category of lymphoma, separate from diffuse large B-cell lymphoma, termed high-grade B-cell lymphoma with translocations involving myc and bcl-2 or bcl-6. These lymphomas, which occur in <10% of cases of diffuse large B-cell lymphoma, have been referred to as double-hit lymphomas (or triple-hit lymphomas if all 3 rearrangements are present). It is important to differentiate these lymphomas from the larger group of double-expressor lymphomas, which have increased expression of MYC and BCL-2 and/or BCL-6 by immunohistochemistry, by using variable cutoff percentages to define positivity. Patients with double-hit lymphomas have a poor prognosis when treated with standard chemoimmunotherapy and have increased risk of central nervous system involvement and progression. Double-hit lymphomas may arise as a consequence of the transformation of the underlying indolent lymphoma. There are no published prospective trials in double-hit lymphoma, however retrospective studies strongly suggest that aggressive induction regimens may confer a superior outcome. In this article, I review my approach to the evaluation and treatment of double-hit lymphoma, with an eye toward future clinical trials incorporating rational targeted agents into the therapeutic armamentarium.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Friedberg JW. How I treat double-hit lymphoma. Blood. 2017. PMID: 28600333. doi:10.1182/blood-2017-04-737320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。